Stalevo 125mg/31.25mg/200mg Tablets / Film-coated
Co-Careldopa with entacapone (Levodopa/Carbidopa/Entacapone)
"125mg, 31.25mg, 200mg"
Novartis Pharma AG
| Pack size | 100's HDPE Bottle |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | CITY MEDICAL STORE |
| Retail Price | 479.50 AED |
Available as:
"75mg, 18.75mg, 200mg" - Tablets / Film-coated
"75mg, 18.75mg, 200mg" - Tablets / Film-coated
50/12.5/200mg - Tablets / Film-coated
200/50/200mg - Tablets / Film-coated
200/50/200mg - Tablets / Film-coated
150/37.5/200mg - Tablets / Film-coated
"125mg, 31.25mg, 200mg" - Tablets / Film-coated
100/25/200mg - Tablets / Film-coated
Indications
Stalevo 125mg/31.25mg/200mg Tablets / Film-coated is used for:
LEVODOPA
For the treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication
CARBIDOPA
For treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
ENTACAPONE
Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic parkinson's disease who experience the signs and symptoms of end-of-dose "wearing-off"
For the treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication
CARBIDOPA
For treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
ENTACAPONE
Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic parkinson's disease who experience the signs and symptoms of end-of-dose "wearing-off"
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Co-Careldopa with entacapone (Levodopa/Carbidopa/Entacapone) :
Mechanism of Action
LEVODOPA
Striatal dopamine levels in symptomatic parkinson's disease are decreased by 60 to 80%, striatal dopaminergic neurotransmission may be enhanced by exogenous supplementation of dopamine through administration of dopamine's precursor, levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier and is decarboxylated to dopamine. This newly formed dopamine then is available to stimulate dopaminergic receptors, thus compensating for the depleted supply of endogenous dopamine
CARBIDOPA
When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic l-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the cns. Carbidopa also inhibits the metabolism of levodopa in the gi tract, thus, increasing the bioavailability of levodopa
ENTACAPONE
The mechanism of action of entacapone is believed to be through its ability to inhibit comt in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome
Striatal dopamine levels in symptomatic parkinson's disease are decreased by 60 to 80%, striatal dopaminergic neurotransmission may be enhanced by exogenous supplementation of dopamine through administration of dopamine's precursor, levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier and is decarboxylated to dopamine. This newly formed dopamine then is available to stimulate dopaminergic receptors, thus compensating for the depleted supply of endogenous dopamine
CARBIDOPA
When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic l-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the cns. Carbidopa also inhibits the metabolism of levodopa in the gi tract, thus, increasing the bioavailability of levodopa
ENTACAPONE
The mechanism of action of entacapone is believed to be through its ability to inhibit comt in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome
Note
Stalevo 125mg/31.25mg/200mg "125mg, 31.25mg, 200mg" Tablets / Film-coated manufactured by Novartis Pharma AG. Its generic name is Co-Careldopa with entacapone (Levodopa/Carbidopa/Entacapone). Stalevo 125mg/31.25mg/200mg is availble in United Arab Emirates.
Farmaco UAE drug index information on Stalevo 125mg/31.25mg/200mg Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Co-Careldopa with entacapone (Levodopa/Carbidopa/Entacapone) :
Tablets / Film-coated
Stalevo 100/25/200mg
100/25/200mg
Novartis Pharma AG
Tablets / Film-coated
Stalevo 125mg/31.25mg/200mg
"125mg, 31.25mg, 200mg"
Novartis Pharma AG
Tablets / Film-coated
Stalevo 150/37.5/200mg
150/37.5/200mg
Novartis Pharma AG
Tablets / Film-coated
Stalevo 200/50/200mg
200/50/200mg
Novartis Pharma AG
Tablets / Film-coated
Stalevo 200/50/200mg
200/50/200mg
Novartis Pharma AG